Labs Make New, Dangerous Synthetic Cannabinoid Drugs Faster Than We Can Ban Them

XLR-11, PB-22, AB-FUBINACA, MAB-CHMINACA, 5F-AMB. These are the cryptic and sometimes unpronounceable names of the most dangerous drugs you’ve never heard of. They are responsible for kidney injury, psychosis, seizures, coma and death.

For instance, AB-FUBINACA was responsible for a spate of recent poisonings at Wesleyan University. And MAB-CHMINACA was associated with more than 100 hospitalizations in Baton Rouge. Neither of these drugs were known to the scientific community until late last year.

These drugs are synthetic cannabinoids — several of the hundreds that have been identified as new “designer drugs” in the past five years. More than 150 were reported in 2013 alone, according to the United Nations Office on Drugs and Crime (UNODC). And police, doctors, scientists and lawmakers are all struggling to identify these new drugs as they hit the streets.

What are synthetic cannabinoids?

Synthetic cannabinoids are molecules designed to mimic the effects of tetrahydrocannabinol, or THC. Like THC, these synthetic cannabinoids target the cannabinoid type 1 receptor (CB1R) in the brain, which is responsible for the psychoactive effects of THC in cannabis.

Although these products are sometimes called “synthetic cannabis” or “fake pot,” both terms are wrong and misleading. They are called cannabinoids not because they are like cannabis, but because they interact with cannabinoid receptors in the brain and elsewhere in the body.

These molecules look chemically different from those found in cannabis, and have very different effects in laboratory tests, and on their users, than actual cannabis does.

These synthetic drugs are manufactured in clandestine labs (mostly in China) for export around the globe. They are usually sprayed onto dry herbs for smoking, and sold inexpensively in foil packets with constantly changing brand names like Spice, K2, Black Mamba, Cloud Nine, Maui Wowie, Mr Nice Guy and countless others. There are literally hundreds of individual products that are known to law enforcement. The brands change as frequently as the drugs themselves.

Underground chemists tweak the structures of these molecules using tricks similar to those employed in the pharmaceutical industry. Unlike Big Pharma, where the goal is to create safer medicines, synthetic cannabinoid designers want to ensure their products evade prohibition but still get their customers “high.” As molecules are identified and banned, drug labs reformulate their products to stay a step ahead. Consumers can never be sure of exactly what drug (or combination of drugs) they are using.

Synthetic cannabinoids are getting stronger and more dangerous

As part of a group of researchers from Australia, New Zealand and the United States, we studied the ability of several synthetic cannabinoids that were commonly available in the past few years to elicit a response from CB1R — the cannabinoid receptor in the brain.

The synthetic cannabinoids we tested that were commonly available during 2011-2013 were several times as potent as THC. But the latest drugs from 2014-2015 were up to 700 times more potent. In these tests most synthetic cannabinoids fully activated CB1R. THC, on the other hand, does not fully activate the receptor. This difference may account for the greater toxicity of these synthetic cannabinoids.

Serious illnesses due to cannabis are exceedingly rare, while those due to synthetic cannabinoid use are becoming more common. A recent report by the Centers for Disease Control and Prevention stated that there were 3,572 calls to poison centers in the United States in the first half of this year due to synthetic cannabinoids, a 229 percent increase from the same period in 2014. More concerning is the fact that clusters of synthetic cannabinoid overdose are associated with the newest drugs.

Thousands of people wound up in emergency rooms as a result of outbreaks in Alabama, Mississippi, and New York in April and May alone. Some of these cases were linked to MAB-CHMINACA, but others are likely due to synthetic cannabinoids so new they have not been identified.

Deaths due to synthetic cannabinoids have been climbing steadily as new variants emerge. During the Mississippi outbreak in April alone there were nine deaths associated with synthetic cannabinoid use.

The DEA can’t keep up with synthetic cannabinoids

In 2012, President Obama signed into law the Synthetic Drug Abuse Prevention Act (SDAPA), which amended the Controlled Substances Act (CSA) of 1970 to place “cannabimimetic agents” — substances that mimic the effects of cannabis — into Schedule I, the most restrictive regulatory category. Schedule I covers drugs like heroin, LSD and actual cannabis. SDAPA designated several specific synthetic cannabinoids, as well as five chemical classes of cannabinoid molecules, as Schedule I substances. But none of the newest synthetic cannabinoids are explicitly covered by SDAPA.

As chemists modify structures to avoid prohibition, the Drug Enforcement Administration (DEA) adds more synthetic cannabinoids to Schedule I. Since January 2013, the DEA has exercised emergency scheduling powers five times to place a total of 25 synthetic cannabinoids into Schedule I. Keep in mind that more than 150 new synthetic cannabinoids were reported by UNODC in 2013.

Once a specific synthetic cannabinoid is placed into Schedule I, related molecules may be considered illegal due to a 1986 amendment to the CSA called the Controlled Substance Analogue Enforcement Act (also called the Federal Analogue Act). The act allows any substance which is “substantially similar” to a Schedule I chemical to be treated as such. But in each instance that similarity needs to be demonstrated in a court of law — which can be a slow process. In effect, that means chemists can modify molecular structures faster than the government can demonstrate that they are illegal or add them to Schedule I.

For instance, a notice of intent to move MAB-CHMINACA, the drug tied to hospitalizations in Baton Rouge and elsewhere, to Schedule I was filed last month. MAB-CHMINACA, a derivative of AB-FUBINACA, only appeared after AB-FUBINACA was placed in Schedule I last year — and that is probably no coincidence.

Using a proactive approach to combat synthetic cannabinoids

Perhaps it is time we stopped reactively banning new synthetic cannabinoids and considered more innovative regulatory approaches.

In the pharmaceutical industry, the patents for a drug typically include related “prophetic” structures, preventing competitors from making modified versions of the drug. Prophetic structures are molecules that have not actually been created yet, but could feasibly be prepared, and are predicted to have similar effects to the protected drug.

A law passed in Texas on September 1 used a similar approach to prohibit more than 1,000 potential synthetic cannabinoids that are anticipated to appear in future based on trends observed now. This is a creative approach, but 1,000 is still a finite number. And the total number of chemically possible synthetic cannabinoids is larger still.

Proactive prohibition may slow the release of new synthetic cannabinoids. Or it could simply catalyze the release of increasingly elaborate and chemically diverse variants. If the past few years are anything to go by, 2016 will bring a new wave of unknown and untested synthetic cannabinoids, and more challenges for police, doctors, scientists and lawmakers.

Samuel Banister, Postdoctoral Research Fellow, Stanford University. Iain S McGregor, Professor of Psychopharmacology and NHMRC Principal Research Fellow, University of Sydney. And Roy Gerona, Assistant Professor, University of California, San Francisco.

This article was originally published on The Conversation. Read the original article.